In July 2010 UK drug regulators approved Botox as a treatment for chronic type of migraine(1). The next to go was FDA (U.S. Food and Drug Administration), which made the same move in October last year(2). The use of botulinum toxin in prevention of migraine attacks has been discussed for more than 10 years but due to extensive research only now has it become possible to make full use of a substance associated mostly with cosmetic surgery. Read full text »